»
«
Offline Showroom in USA
Post Offer Free
MOSINTER GROUP LIMITED
MOSINTER GROUP LIMITED

China Regorafenib CAS 755037-03-7 BAY 73-4506 regorafenib BAY 73-4506 manufacturer

5th

Gold Index: 88659

You are here: home  > Pharmaceutical Chemicals API  > Antineoplastic Drugs API  > Regorafenib CAS 755037-03-7 BAY 73-4506 regorafenib BAY 73-4506

Regorafenib CAS 755037-03-7 BAY 73-4506 regorafenib BAY 73-4506 

Payment Terms: T/T,L/C,WU 
Place of Origin: Shandong, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: C21H15ClF4N4O3
Production Capacity: 400 Kilogram/Year
Delivery Date: within 7 days
Molecular Formula: C21H15ClF4N4O3
Specification: CP/USP/EP
Density: 1.491 g/cm3
flash point: 264.3 °C
Means of Transport: Ocean,Land,Air
Packing: According to request of cus...
Brand: MOSINTER
Molecular Weight: 482.82
Content: 98%
Boiling point: 513.4 °C at 760 mmHg

Regorafenib demonstrated to increase the overall survival of patients with metastatic colorectal cancer

Regorafenib(CAS: 755037-03-7)


Item

Index

Molecular Formula

C21H15ClF4N4O3

Molecular Weight

482.82

Specification

CP/USP/EP

Content

98%

Regorafenib (BAY 73-4506, commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. It is currently being studied as a potential treatment option in multiple tumor types.


Approvals and indications

Metastatic colorectal cancer

Regorafenib demonstrated to increase the overall survival of patients with metastatic colorectal cancer and has been approved by the US FDA on September 27, 2012.

Advanced gastrointestinal stromal tumours

On February 25, 2013 the US FDA expanded the approved use to treat patients with advanced gastrointestinal stromal tumors that cannot be surgically removed and no longer respond to other FDA-approved treatments for this disease. In a clinical study with 199 patients regorafenib treated patients had a delay in tumor growth (progression-free survival) that was, on average, 3.9 months longer than patients who were given placebo.

bigPhoto
skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Other products from this supplier

Company Info

MOSINTER GROUP LIMITED [China (Mainland)]

sgs ico Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: